Telix Pharmaceuticals Ltd. TLX 深 沪
等待开盘 10-24 09:30:00 美东时间
10.88
+0.100
+0.93%
华盛通- 最 高11.00
- 今 开10.85
- 成交量 8.99万股
- 最 低 10.85
- 昨 收 10.78
- 总市值 36.45亿
- 52周最高 30.36
- 市盈率 静 114.05
- 换手率 0.03%
- 52周最低 8.93
- 委 比 -39.94%
- 总股本 3.35亿
- 历史最高 30.36
- 量 比 0.91
- 振 幅 1.39%
- 历史最低 8.93
- 每 手 1
- 风险率 2.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
Melbourne, Australia and Indianapolis – Telix Pharmaceuticals announced that updated guidelines from leading nuclear medicine societies now include its investigational PET agent, TLX250-CDx, for imaging renal masses. The expert panel highlighted TLX250-CDx as a non-invasive, accurate method for diagnosing clear cell renal cell carcinoma (ccRCC), referencing data from the successful Phase 3 ZIRCON trial. The inclusion marks a significant step towa...
10-23 11:00
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
Telix Pharmaceuticals has initiated a Phase 1 clinical trial for TLX090, a radiopharmaceutical targeting bone metastases-related pain. Designed to deliver targeted radiation, TLX090 aims to minimize damage to healthy tissues while providing long-lasting pain relief. The SOLACE trial, enroll up to 33 patients, evaluates safety, efficacy, and pharmacokinetics. Existing treatments like opioids and EBRT have significant limitations, making TLX090's n...
10-22 20:00
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance
Telix Pharmaceuticals posts 53% Q3 revenue growth to $206 million, lifts FY25 guidance to up to $820 million amid strong PSMA imaging and reimbursement gains.
10-15 02:11
Telix Pharmaceuticals boosts FY25 guidance after strong Q3
Telix Pharmaceuticals (OTCPK:TLPPF) reported Q3 2025 revenue of $206M, up 53% year-over-year. FY 2025 revenue guidance raised to $800–$820 million, up from prior forecasts. R&D spending to rise 20–25%...
10-14 15:51
Telix Pharmaceuticals Sees Q3 Sales $206.000M
Telix Pharmaceuticals (NASDAQ:TLX) sees Q3 sales of $206.000 million.
10-14 15:21
Telix Pharmaceuticals Raises FY2025 Sales Guidance from $770.000M-$800.000M to $800.000M-$820.000M
Telix Pharmaceuticals (NASDAQ:TLX) raises FY2025 sales outlook from $770.000 million-$800.000 million to $800.000 million-$820.000 million.
10-14 15:21
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Telix Pharmaceuticals reported unaudited Q3 2025 revenue of $206 million, up 53% year-over-year. Key highlights include full reimbursement for Gozellix in the U.S., Illuccix approvals in 19 European markets and the UK, and the start of BiPASS™ trial for prostate cancer diagnosis. Clinical trial progress includes first patients dosed in ProstACT and TLX400 studies. Manufacturing facilities in Australia and Japan received radiation licenses. FY 202...
10-14 06:22
Telix Pharmaceuticals Announces Cessation of Securities
Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an update. Telix Pharmaceutic...
10-10 06:39
Telix Pharmaceuticals Expands ASX Quotation with New Securities
Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals...
10-10 06:28
远大医药全球创新温度敏感性栓塞剂在中国的注册性临床研究完成全部患者入组
（来源：远大医药） · GPN00289是一款获得国家药监局创新型医疗器械资质认定的温度敏感性栓塞材料，用于治疗富血管的良性及恶性肿瘤； ·GP...
10-09 18:20
